71650-77-6

Upstream product

• 542-92-7 cyclopenta-1,3-diene 
• 1122-91-4 4-bromo-benzaldehyde 
• 589-87-7 1,4-bromoiodobenzene 
• 74-86-2 acetylene 

Relevant academic research and scientific papers

Modified cyclopentadienyl molybdenum compounds with enhanced cytotoxic activity towards MOLT-4 leukaemia cells

A series of new cyclopentadienyl molybdenum compounds bearing substituted phenanthroline ligands [(η5-C5H4CH2C6H4X-4)Mo(CO)2(N,NL)][BF4] (X?=?F, Cl, Br; su

Synthesis of plasmodione metabolites and 13C-enriched plasmodione as chemical tools for drug metabolism investigation

Malaria is a tropical parasitic disease threatening populations in tropical and sub-tropical areas. Resistance to antimalarial drugs has spread all over the world in the past 50 years, thus new drugs are urgently needed. Plasmodione (benzylmenadione series) has been identified as a potent antimalarial early lead drug, acting through a redox bioactivation on asexual and young sexual blood stages. To investigate its metabolism, a series of plasmodione-based tools, including a fully 13C-labelled lead drug and putative metabolites, have been designed and synthesized for drug metabolism investigation. Furthermore, with the help of UHPLC-MS/MS, two of the drug metabolites have been identified from urine of drug-treated mice.

Reaction discovery using acetylene gas as the chemical feedstock accelerated by the stop-flow micro-tubing reactor system

Acetylene gas has been applied as a feedstock under transition-metal catalysis and photo-redox conditions to produce important chemicals including terminal alkynes, fulvenes, and fluorinated styrene compounds. The reaction discovery process was accelerated through the use of stop-flow micro-tubing reactors. This reactor prototype was developed by joining elements from both continuous micro-flow and conventional batch reactors, which was convenient and effective for gas/liquid reaction screening. Notably, the developed transformations were either inefficient or unsuccessful in conventional batch reactors. Its success relies on the unique advantages provided by this stop-flow micro-tubing reactor system.

SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION

This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.